Compare Medpace Holdings Inc (MEDP) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Payoneer Global Inc — how do they compare? Medpace Holdings Inc trades at $601.3 (market cap $16.90B), while Payoneer Global Inc trades at $7.09 (market cap $2.40B). The key difference: Medpace Holdings Inc is far larger — about 7× Payoneer Global Inc's market cap. Which is the better fit depends on your goals.
| MEDP | PAYO | |
|---|---|---|
Market Cap | $16.90B | $2.40B |
Sector | Technology | Technology |
52-Week High | $620.59 | $7.17 |
52-Week Low | $393.42 | $4.27 |
Enterprise Value | $16.52B | $2.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $600.32, down 0.35% on the day, with a bullish technical signal supported by moving averages. The stock shows strong fundamentals with Q2 2026 earnings beating estimates at $4.25 per share versus $3.98 expected, and revenue growth projected from $2.53B in 2025 to $2.8B in 2026. Recent news highlights record bookings and raised guidance, though valuation ratios remain elevated with a P/E of 35.58 and P/B of 38.95.
Outlook remains positive driven by earnings momentum and strong backlog visibility, but risks include premium valuation compression and ongoing legal scrutiny. Analyst consensus is cautious with 73.7% hold ratings, though institutional interest persists with California State Teachers Retirement System increasing its position by 22.1% in Q1 2026.
Payoneer (PAYO) trades at $7.07, down 0.28% on the day, with a bullish technical signal from moving averages and an oversold RSI. Revenue grew to $821.16M in 2025, but net income fell to $73.19M, and Q2 2026 earnings missed estimates. The company is set to be acquired by Nuvei for $7.40 per share, pending shareholder approval, amid legal scrutiny over deal fairness.
The outlook is acquisition-driven, with upside limited to the $7.40 buyout price unless a higher bid emerges. Risks include integration challenges, earnings volatility, and legal disputes. Analysts maintain a buy consensus with an $8.20 target, suggesting potential gains if the deal proceeds smoothly, but caution is warranted due to recent profit margin compression.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
